Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.1 (
chymotrypsin
)
10,938
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
N-acetylmuramoyl-l-alanine amidase
(
NAMLAA
) hydrolyzes bacterial peptidoglycan and is present in human serum. A peptidoglycan-recognition protein 2 (PGLYRP2) is expressed in human liver and has
N-acetylmuramoyl-l-alanine amidase
activity. Here, we determined the amino acid sequences of human serum
NAMLAA
and liver PGLYRP2 and tested the hypothesis that serum
NAMLAA
and PGLYRP2 are the same protein. Liver PGLYRP2 and serum
NAMLAA
had the same mass determined by mass spectrometry and polyacrylamide gel electrophoresis, and both proteins and recombinant PGLYRP2 reacted with polyclonal anti-
NAMLAA
and anti-PGLYRP2 antibodies, and with monoclonal anti-
NAMLAA
antibodies. Digestion of serum
NAMLAA
with trypsin,
chymotrypsin
, or trypsin plus V8 protease, or with CNBr yielded, respectively, 37, 40, and 3 overlapping peptides that matched 100% and covered 81% of the deduced amino acid sequence of mature PGLYRP2. These peptides overlapped all exon-intron junctions indicating no alternative splice forms. Digestion of liver PGLYRP2 with trypsin yielded 23 peptides that matched 100% and covered 44% of the deduced amino acid sequence of mature PGLYRP2. Serum
NAMLAA
had a C398-C404 disulfide, partial phosphorylation of S218, and deamidation of N253 and N301. These results indicate that serum
NAMLAA
and liver PGLYRP2 are the same protein encoded by the pglyrp2 gene.
...
PMID:Identification of serum N-acetylmuramoyl-l-alanine amidase as liver peptidoglycan recognition protein 2. 1605 49